


Exhibit 99.1



Fourth Quarter 2007 Webcast February 7, 2008

Safe Harbor Statement

Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on February 7, 2008, and Alcon does not undertake any obligation to update any of the forward-looking statements or forward-looking information. Although Alcon believes that these statements are based on reasonable assumptions within the bounds of its knowledge of its businesses and operations, there are a number of factors that may cause actual results to differ from these statements. Factors that might cause these differences include, but are not limited to, the uncertainty of market acceptance of our products by the worldwide medical community; uncertainty of clinical trial results for expanded FDA approval submissions for our current products and initial approval of our products under development; product liability claims; losses from litigations; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self insured; manufacturing issues; and risks inherent in international transactions. For additional factors, which could cause actual results to differ from expectations, reference is made to the periodic reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934 as amended. Additional information about risk factors also can be found in the Company's Form 20-F filed with the SEC dated March 19, 2007, under the heading "Risk Factors". All these documents are available publicly and upon request from the Alcon Investor Relations Department at 817-551-8805 or www.alcon.com.

Business Overview

Cary Rayment

Chairman, President & CEO

Sales Highlights


4th Qtr	Q4 07	Q4 06	Growth
<i>(dollars in millions)</i>			
Global Sales	\$ 1,469.7	\$ 1,224.9	20.0%
		Constant Currency*	14.0%

Full Year	FY 07	FY 06	Growth
<i>(dollars in millions)</i>			
Global Sales	\$ 5,599.6	\$ 4,896.6	14.4%
		Constant Currency*	11.0%

* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

FY 2007 Geographic Sales and Growth

FY 2007 Sales by Geography




(dollars in millions)

Pharmaceutical Sales


4th Qtr

+21.5%



Full Year


+15.3%



(dollars in millions)

Glaucoma Growth Rates by Competitor

Full Year 2007



Source: Company Filings

Gaining Market Share in Pharmaceuticals


<u>RX Growth</u>	Global Sept YTD		US FY 2007	
	Brand	Market	Brand	Market
Travatan [®] + Travatan Z [®] + DuoTrav [™]	22.3%	9.2%	21.3%	6.5%
Azopt [®]	14.9%	5.7%	15.7%	5.5%
Vigamox [®] *	45.1%	8.1%	7.5%	3.5%
Tobradex [®]	7.8%	6.7%	-0.8%	1.7%
Nevanac [®]	29.6%	2.2%	24.2%	20.6%
Patanol [®] + Pataday [™]	37.8%	6.2%	4.3%	-1.9%
CiproDex [®] *	6.8%	2.6%	5.4%	-3.4%

* Moxifloxacin, the active ingredient in **Vigamox[®]**, is licensed to Alcon from Bayer Healthcare AG.
CiproDex[®] is a registered trademark of Bayer AG and licensed to Alcon by Bayer Healthcare AG.


Source: Global-IMS US-WK Health

Surgical Sales

4th Qtr




Full Year



(dollars in millions)


Global Growth in Cataract Products

Percent Growth in Cataract Products – FY 2007



Source: Global procedure growth from Market Scope


US Premium IOL Sales Trend



Consumer Eye Care Sales


4th Qtr

+14.5%




Full Year

+14.6%



(dollars in millions)

US Market Share Since April 2007



*OPTI-FREE® EXPRESS® and RepleniSH® combined

Source: AC Nielsen

Financial Review

Rick Croarkin

Senior Vice President, Finance and Chief Financial Officer

Non-GAAP Adjustments

	<u>Q4</u>		<u>Full Year</u>	
	<u>Op Profit</u>	<u>After Tax</u>	<u>Op Profit</u>	<u>After Tax</u>
<u>2007</u>				
WaveLight Acquisition & Refractive Integration	\$ 21.1	\$ 16.8	\$ 26.4	\$ 20.2
Refractive Impairment	--	--	32.7	20.8
<u>2006</u>				
Patent Lawsuit Settlement	\$ --	\$ --	\$ (119.0)	\$ (97.5)
Refractive Impairment	--	--	144.8	92.0
			<i>(dollars in millions)</i>	

* Non-GAAP measures – Adjustments are presented on the reconciliation slides at the end of this presentation and in the earnings release dated February 6, 2008.

Gross Profit

4th Qtr		Q4 07	% of Sales	Q4 06	% of Sales
<i>(dollars in millions)</i>					
Gross Profit	Reported	\$ 1,098.4	74.7%	\$ 924.7	75.5%
	Non-GAAP Adjustment*	(1.9)		--	
	Adjusted	\$ 1,096.5	75.4%	\$ 924.7	75.5%

Full Year		FY 07	% of Sales	FY 06	% of Sales
<i>(dollars in millions)</i>					
Gross Profit	Reported	\$ 4,201.4	75.0%	\$ 3,681.5	75.2%
	Non-GAAP Adjustment*	25.3		19.1	
	Adjusted	\$ 4,226.7	75.7%	\$ 3,700.6	75.6%

* Non-GAAP measures – Adjustments are presented on the reconciliation slides at the end of this presentation and in the earnings release dated February 6, 2008.

Operating Profit

4th Qtr		Q4 07		% of Sales	Q4 06		% of Sales
<i>(dollars in millions)</i>							
Operating Profit	Reported	\$	477.4	32.5%	\$	392.9	32.1%
	Non-GAAP Adjustment*		21.1			--	
	Adjusted	\$	498.5	34.3%	\$	392.9	32.1%

Full Year		FY 07		% of Sales	FY 06		% of Sales
<i>(dollars in millions)</i>							
Operating Profit	Reported	\$	1,883.1	33.6%	\$	1,572.1	32.1%
	Non-GAAP Adjustment*		59.1			25.8	
	Adjusted	\$	1,942.2	34.8%	\$	1,597.9	32.6%

* Non-GAAP measures – Adjustments are presented on the reconciliation slides at the end of this presentation and in the earnings release dated February 6, 2008.

Net Earnings

4th Qtr		Q4 07		% of Sales	Q4 06		% of Sales
<i>(dollars in millions)</i>							
Net Earnings	Reported	\$	376.5	25.6%	\$	354.7	29.0%
	Non-GAAP Adjustment*		16.8			--	
	Adjusted	\$	393.3	27.0%	\$	354.7	29.0%

Full Year		FY 07		% of Sales	FY 06		% of Sales
<i>(dollars in millions)</i>							
Net Earnings	Reported	\$	1,586.4	28.3%	\$	1,348.1	27.5%
	Non-GAAP Adjustment*		41.0			(5.5)	
	Adjusted	\$	1,627.4	29.1%	\$	1,342.6	27.4%

* Non-GAAP measures – Adjustments are presented on the reconciliation slides at the end of this presentation and in the earnings release dated February 6, 2008.

Diluted EPS

4 th Qtr		Q4 07		Q4 06		Growth
Diluted EPS	Reported	\$	1.25	\$	1.16	7.8%
	Non-GAAP Adjustment*		0.06		--	
	Adjusted	\$	1.31	\$	1.16	12.9%

Full Year		Q4 07		Q4 06		Growth
Diluted EPS	Reported	\$	5.25	\$	4.37	20.1%
	Non-GAAP Adjustment*		0.14		(0.02)	
	Adjusted	\$	5.39	\$	4.35	23.9%

* Non-GAAP measures – Adjustments are presented on the reconciliation slides at the end of this presentation and in the earnings release dated February 6, 2008.

Cash Flow Analysis

Cash Flow from Operations



% Reinvested
into PPE

17.2%


14.0%

13.1%

15.8%

15.5%


Net Cash Returned to Shareholders



* Dividend payout ratio represents dividends as a percentage of prior year's reported net earnings

2008 Full Year Financial Guidance

- **Sales range of \$6,175 to \$6,275 million**
- **Diluted earnings per share range of \$6.24 to \$6.30**
- **Includes costs to establish Swiss Shared Service and Marketing Centers and to integrate refractive operations**



Q4 2007 Non-GAAP Adjustments

(dollars in millions, except per share amounts)

	<u>Reported</u>	<u>WaveLight Acquisition & Refractive Integration</u>	<u>Non-GAAP Adjusted*</u>
Sales	\$ 1,469.7	\$ (15.1)	\$ 1,454.6
Cost of goods sold	371.3	(13.2)	358.1
Gross profit	1,098.4	(1.9)	1,096.5
Selling, general and administrative	441.6	(7.9)	433.7
Research and development	160.0	(4.3)	155.7
In process R & D	9.3	(9.3)	--
Amortization of intangibles	10.1	(1.5)	8.6
Operating income	477.4	21.1	498.5
Other income	2.0	--	2.0
Earnings before income taxes	479.4	21.1	500.5
Income taxes	102.9	4.3	107.2
Net earnings	\$ 376.5	\$ 16.8	\$ 393.3
Diluted EPS	\$ 1.25	\$ 0.06	\$ 1.31

*The results as adjusted above are non-GAAP measures and are provided to help investors better compare results of operations from 2007 and 2006.

FY 2007 Non-GAAP Adjustments

(dollars in millions, except per share amounts)

	<u>Reported</u>	<u>Refractive Impairment</u>	<u>WaveLight Acquisition & Refractive Integration</u>	<u>Non-GAAP Adjusted*</u>
Sales	\$ 5,599.6	\$ --	\$ (15.1)	\$ 5,584.5
Cost of goods sold	1,398.2	(24.0)	(16.4)	1,357.8
Gross profit	4,201.4	24.0	1.3	4,226.7
Selling, general and administrative	1,694.0	--	(7.9)	1,686.1
Research and development	564.3	--	(6.4)	557.9
In process research and development	9.3	--	(9.3)	--
Amortization of intangibles	50.7	(8.7)	(1.5)	40.5
Operating income	1,883.1	32.7	26.4	1,942.2
Other income	45.9	--	--	45.9
Earnings before income taxes	1,929.0	32.7	26.4	1,988.1
Income taxes	342.6	11.9	6.2	360.7
Net earnings	\$ 1,586.4	\$ 20.8	\$ 20.2	\$ 1,627.4
Diluted EPS	\$ 5.25	\$ 0.07	\$ 0.07	\$ 5.39

*The results as adjusted above are non-GAAP measures and are provided to help investors better compare results of operations from 2007 and 2006.

FY 2006 Non-GAAP Adjustments

(dollars in millions, except per share amounts)

	Non-GAAP Adjustment			
	<u>Reported</u>	<u>Patent Lawsuits Settlement</u>	<u>Refractive Impairment</u>	<u>Non-GAAP Adjusted*</u>
Sales	\$ 4,896.6	\$ --	\$ --	\$ 4,896.6
Cost of goods sold	1,215.1	--	(19.1)	1,196.0
Gross profit	3,681.5	--	19.1	3,700.6
Selling, general and administrative	1,398.5	119.0	--	1,517.5
Research and development	512.1	--	--	512.1
Amortization of intangibles	198.8	--	(125.7)	73.1
Operating income	1,572.1	(119.0)	144.8	1,597.9
Other income	44.8	--	--	44.8
Earnings before income taxes	1,616.9	(119.0)	144.8	1,642.7
Income taxes	268.8	(21.5)	52.8	300.1
Net earnings	\$ 1,348.1	\$ (97.5)	\$ 92.0	\$ 1,342.6
Diluted EPS	\$ 4.37	\$ (0.32)	\$ 0.30	\$ 4.35

*The results as adjusted above are non-GAAP measures and are provided to help investors better compare results of operations from 2007 and 2006.